Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion.
The final analysis will be limited to individuals in whom the volume of ICM administered during the index procedure was between 50 and 500 mL and for whom both pre- and post-procedure serum creatinine measurements were available.
The primary objective of the study is the effect of short-term and long-term SGLT2i therapy on the occurrence of CI-AKI in patients undergoing diagnostic or therapeutic procedures with ICM.
The use of radiological imaging methods requiring iodine-based contrast media (ICM) has been steadily increasing in recent years. Contrast-induced acute kidney injury (CI-AKI), formerly referred to as contrast-induced nephropathy (CIN), is one of the most common causes of acute kidney injury in patients undergoing diagnostic or therapeutic procedures involving ICM.
The study was designed as a retrospective, single-centre, cross-sectional, cohort, case-control study. All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion. The final analysis will be limited to individuals in whom the volume of ICM administered during the index procedure was between 50 and 500 mL and for whom both pre- and post-procedure serum creatinine measurements were available.
The primary objective of the study is the effect of short-term and long-term SGLT2i therapy on the occurrence of CI-AKI in patients undergoing diagnostic or therapeutic procedures with ICM.
The analysis of the baseline characteristics of the study population is planned.
Based on the results of the study, a meta-analysis combining the results of previously published studies with those of the present study will be performed.
Key variables to be analyzed: type and volume of ICM; serum creatinine concentration at baseline, 24 h, 48 h, and 72 h after the procedure; eGFR at baseline, 24 h, 48 h, and 72 h; use of SGLT2i within 3 days prior to the procedure; long-term use of SGLT2i; type of SGLT2i administered.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients using any flozin at the time of coronary intervention | Patients who underwent percutaneous coronary procedures while using empagliflozin or dapagliflozin in a standard 10 mg daily dose |
| |
| Patients not using any flozin | Patients who underwent percutaneous coronary interventions but were not using any flozins |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Flozin | Drug | Patients who underwent percutaneous coronary interventions while using empagliflozin or dapagliflozin |
|
| Measure | Description | Time Frame |
|---|---|---|
| Occurrence of Contrast-Induced Acute Kidney Injury (CI-AKI) | Occurrence of CI-AKI defined as an increase in serum creatinine concentration of ≥0.5 mg/dL (44.2 μmol/L) or >25% compared with baseline within 72 h after intravascular administration a contrast medium agent | 0-72 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Creatinine change after coronary procedure | Change in serum creatinine concentration before and after the index procedure | 0-72 hours |
| eGFR after coronary procedure | Change in eGFR before and after the index procedure |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Retrospective analysis of data obtained from patients hospitalized between 2020 and 2025 in the Department of Cardiology and Internal Medicine, who underwent coronary angiography or PCI.
The final analysis will be limited to individuals in whom the volume of ICM administered during the index procedure was between 50 and 500 mL and for whom both pre- and post-procedure serum creatinine measurements were available
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Piotr Niezgoda, MD, PhD | Contact | +48525854023 | piotr.niezgoda1986@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Jacek Kubica, Prof. | Collegium Medicum w Bydgoszczy | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Collegium Medicum w Bydgoszczy | Recruiting | Bydgoszcz | 85-094 | Poland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003324 | Coronary Artery Disease |
| D058186 | Acute Kidney Injury |
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C570240 | empagliflozin |
| C529054 | dapagliflozin |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 0-72 hours |
| Real-life incidence of AKI | the true incidence of CI-AKI in real-world clinical setting | 0-72 hours |
| incidence of CI-AKI in diabetic patients | the effect of SGLTi on the occurrence of CI-AKI in patients with and without type 2 diabetes mellitus | 0-72 hours |
| incidence of CI-AKI in ACS patients using flozins | the effect of SGLTi on the occurrence of CI-AKI in patients with and without acute coronary syndrome | 0-72 hours |
| incidence of CI-AKI on empagliflozin vs dapagliflozin | the effects of dapagliflozin versus empagliflozin on the occurrence of CI-AKI in the overall study population | 0-72 hours |
| D001161 |
| Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |